Skip to main content
Erschienen in: Journal of Cancer Survivorship 5/2020

26.05.2020

Influence of provider recommendations to restart vaccines after childhood cancer on caregiver intention to vaccinate

verfasst von: Echo L. Warner, Perla L. Vaca Lopez, Deanna Kepka, Karely Mann, Heydon K. Kaddas, Douglas Fair, Mark Fluchel, Elizabeth D. Knackstedt, Samantha T. Pannier, Laura Martel, Anne C. Kirchhoff

Erschienen in: Journal of Cancer Survivorship | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We studied the influence of oncology and primary care provider (PCP) recommendations on caregiver intentions to restart vaccines (e.g., catch-up or boosters) after cancer treatment.

Methods

We surveyed primary caregivers ages 18 or older with a child who had completed cancer treatment 3–36 months prior (N = 145) about demographics, child’s vaccination status, and healthcare factors (e.g., provider recommendations, barriers, preferences for vaccination). We compared these factors by caregiver’s intention to restart vaccines (“vaccine intention” vs. “no intent to vaccinate”) using bivariate and multivariable analyses.

Results

Caregivers were primarily ages 30–39 years (54.9%), mothers (80.6%), college graduates (44.4%), non-Hispanic (89.2%), and married (88.2%). Overall, 34.5% of caregivers did not know which vaccines their child needed. However, 65.5% of caregivers reported vaccine intention. Fewer caregivers with no intention to vaccinate believed that vaccinating their child helps protect others (85.4 vs. 99.0%, p < 0.01), that vaccines are needed when diseases are rare (83.7 vs. 100.0%, p < 0.01), and that vaccines are safe (80.4 vs. 92.6%, p = 0.03) and effective (91.5 vs. 98.9%, p = 0.04) compared with vaccine intention caregivers, respectively. Provider recommendations increased caregivers’ likelihood of vaccine intention (oncologist RR = 1.65, 95% CI 1.27–2.12, p < 0.01; PCP RR = 1.51, 95% CI 1.19–1.94, p < 0.01).

Conclusions

Provider recommendations positively influence caregivers’ intention to restart vaccines after childhood cancer. Guidelines are needed to support providers in making tailored vaccine recommendations.

Implications for Cancer Survivors

Timely vaccination after childhood cancer protects patients against vaccine-preventable diseases during survivorship. Caregivers may benefit from discussing restarting vaccinations after cancer with healthcare providers.
Literatur
2.
Zurück zum Zitat Children’s Oncology Group. Long-term follow-up guidelines: for survivors of childhood, adolescent, and young adult cancers. In: Group CsO, editor. Version 4.0 ed2013. Children’s Oncology Group. Long-term follow-up guidelines: for survivors of childhood, adolescent, and young adult cancers. In: Group CsO, editor. Version 4.0 ed2013.
3.
Zurück zum Zitat Long-term follow-up care for pediatric cancer survivors. Pediatrics. 2009;123(3):906-15. doi:10.1542/peds.2008-3688. Long-term follow-up care for pediatric cancer survivors. Pediatrics. 2009;123(3):906-15. doi:10.1542/peds.2008-3688.
20.
Zurück zum Zitat Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM. Parental vaccine safety concerns in 2009. Pediatrics. 2010;125(4):654–9.CrossRef Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM. Parental vaccine safety concerns in 2009. Pediatrics. 2010;125(4):654–9.CrossRef
25.
Zurück zum Zitat Tonorezos ES, Barnea D, Cohn RJ, Cypriano MS, Fresneau BC, Haupt R, et al. Models of care for survivors of childhood cancer from across the globe: advancing survivorship care in the next decade. J Clin Oncol. 2018;36(21):2223–30.CrossRef Tonorezos ES, Barnea D, Cohn RJ, Cypriano MS, Fresneau BC, Haupt R, et al. Models of care for survivors of childhood cancer from across the globe: advancing survivorship care in the next decade. J Clin Oncol. 2018;36(21):2223–30.CrossRef
26.
Zurück zum Zitat Mouw MS, Wertman EA, Barrington C, Earp JAL. Care transitions in childhood cancer survivorship: providers’ perspectives. J Adolesc Young Adult Oncol. 2017;6(1):111–9.CrossRef Mouw MS, Wertman EA, Barrington C, Earp JAL. Care transitions in childhood cancer survivorship: providers’ perspectives. J Adolesc Young Adult Oncol. 2017;6(1):111–9.CrossRef
27.
Zurück zum Zitat Institute of Medicine. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press; 2006. Institute of Medicine. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press; 2006.
28.
Zurück zum Zitat Seehusen DA, Baird D, Bode D. Primary care of adult survivors of childhood cancer. Am Fam Physician. 2010;81(10):1250–5.PubMed Seehusen DA, Baird D, Bode D. Primary care of adult survivors of childhood cancer. Am Fam Physician. 2010;81(10):1250–5.PubMed
Metadaten
Titel
Influence of provider recommendations to restart vaccines after childhood cancer on caregiver intention to vaccinate
verfasst von
Echo L. Warner
Perla L. Vaca Lopez
Deanna Kepka
Karely Mann
Heydon K. Kaddas
Douglas Fair
Mark Fluchel
Elizabeth D. Knackstedt
Samantha T. Pannier
Laura Martel
Anne C. Kirchhoff
Publikationsdatum
26.05.2020
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 5/2020
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-020-00890-y

Weitere Artikel der Ausgabe 5/2020

Journal of Cancer Survivorship 5/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.